EFFICACY AND SAFETY BY CYTOGENETIC RISK STATUS: PHASE 3 STUDY (ASPIRE) OF CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA

H. Avet-Loiseaul, R. Fonseca, I Siege D., Ma Dimopoulos, I. Spicka,T. Masszi,R. Hajek,L. Rosinol, V. Garanava-Marinova, G. Mihaylavlo,V. Maisnar,M. V. Mateos,M. Wang,R. Niesvizky,A. Oriol,A. Jakubowiak,J. Minarik,A. Palumbo,W. Bensinger,V. Kukreti, D. Ben-Yehuda,M. Tonda, M. Obreja,P. Moreau

HAEMATOLOGICA(2016)

引用 0|浏览7
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要